Patients with acute promyelocytic leukemia (APL) are characterized by
the presence of a t(15;17) chromosomal translocation. The fusion prote
in PML-RAR alpha encoded from the breakpoint can form a heterodimer an
d acts as a dominant negative inhibitor against the normal function of
PML. Recently we demonstrated that PML is a growth suppressor and tra
nscription suppressor expressed in all cell lines tested. We also foun
d that PML suppresses the clonogenicity and tumorigenicity of APL-deri
ved NB4 cells, as well as the transformation of rat embryo fibroblasts
by cooperative oncogenes and NIH/3T3 by neu. Overexpression of PML in
human tumor cell lines induces a remarkable reduction in growth rate
in vitro and in vivo. More recently, we have shown that PML is a phosp
hoprotein associated with the nuclear matrix and that its expression i
s cell cycle related. PML expression is altered during human oncogenes
is, implying that PML may be an anti-oncogene involved not only in APL
but also in other oncogenic events, Mutation analysis of the function
al domains of PML demonstrated that its ability to form PML nuclear bo
dies or PODs (PML oncogenic domains) is essential for suppressing grow
th and transformation. In light of the above studies it appears that d
isruption of the normal function of PML plays a critical role in the p
athogenesis of APL.